I was not talking about Sawston or Regulatory Approval in that post.
I would argue that your point is really not where the company is headed, apparently, but that was not my point in the post you commented on. There is no evidence that they are still working with Fraunhoffer,, though you raise interesting points, they are already building Sawston for themselves, and Cognate I do believe they can scale up and likely will be part of their plan, but their focus is actually Sawston and then also scaling Flaskwork's technology at Sawston, most likely, first. Cognate is set for manufacturing of DCVax Direct as well.
But Sawston as a point related to approval by the regulator was NOWHERE in the previous comment to which you responded nor in any comment that I can think of in recent weeks or months. So I am not sure where that response came from.